Immune Checkpoint Inhibitors for Esophageal Cancer: OAJBS Publishers

Immune Checkpoint Inhibitors for Esophageal Cancer by Shun Yamamoto* in Open Access Journal of Biomedical Science (OAJBS)


Esophageal cancer (EC) is the seventh most common cancer, and patients with advanced EC have a poor prognosis. Recently, nivolumab and pembrolizumab, two immune checkpoint inhibitors (ICIs) that inhibit programmed cell death protein 1, have begun to be used for the treatment of advanced esophageal squamous cell carcinoma (ESCC). Based on the ATTRACTION-3 and KEYNOTE-181 trials, the use of nivolumab and pembrolizumab (only in programmed cell death ligand 1-positive cases) was approved for treatment by the US Federal Drug Administration for the treatment of patients with advanced ESCC. In addition, the CheckMate-577 and the KEYNOTE-590 trials have shown survival benefits for postoperative nivolumab in patients with resectable EC and for first line pembrolizumab plus doublet chemotherapy in patients with advanced EC, respectively. Many trials to evaluate ICI-containing treatments are ongoing, and these new treatments are expected to improve the clinical outcomes of patients with EC.
https://biomedscis.com/fulltext/immune-checkpoint-inhibitors-for-esophageal-cancer.ID.000267.php

To Know More About Open Access Journal of Biomedical Science Please Visit: Biomedscis

Are Click on:  https://Biomedscis.Com/

Comments

Popular posts from this blog

Facile Synthesis of Chitosan Nanoparticle with Different Features and Histopathological Ultrastructural Study on The Effect of Its Bio-complex with Bovine Serum Albumin: OAJBS Publishers

Carlos Gravato | Biomedscis Editor

Review on Analysis of Breast Tumor with Methods of Treatment: OAJBS Publishers